Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ATELVIA vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
Treatment of osteoporosis in postmenopausal women,Treatment of osteoporosis in men at high risk of fracture,Treatment and prevention of glucocorticoid-induced osteoporosis,Off-label: Paget's disease of bone
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Risedronate is not metabolized and is excreted unchanged primarily by the kidneys (<5% metabolized). No cytochrome P450 enzymes involved.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Approximately 99% bound to plasma proteins, primarily albumin.
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
Mean Vd is 6.2 L/kg (range 4-10 L/kg), indicating extensive distribution into bone and soft tissues.
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral bioavailability is approximately 0.7% (range 0.5-1.0%) under fasting conditions; food and calcium-containing beverages significantly reduce absorption.
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
Contraindicated in patients with Cr Cl <15 m L/min. No dose adjustment required for Cr Cl ≥15 m L/min. For Cr Cl 15-30 m L/min, use with caution due to limited data.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use caution.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Not approved for use in pediatric patients; safety and efficacy not established in children.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
No specific dose adjustment required. Consider potential renal impairment (assess Cr Cl) and increased risk of gastrointestinal adverse effects. Ensure adequate calcium and vitamin D intake.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
No FDA black box warning.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Hypocalcemia must be corrected before therapy initiation,Severe renal impairment (Cr Cl <30 m L/min): not recommended,Osteonecrosis of the jaw (ONJ) with invasive dental procedures,Atypical femur fractures with long-term use,Upper gastrointestinal adverse events (e.g., esophagitis, ulcers) if taken incorrectly,Hypersensitivity reactions including angioedema
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hypocalcemia,Creatinine clearance <30 m L/min,Inability to stand or sit upright for at least 30 minutes,History of esophageal disorders (e.g., stricture, achalasia)
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
Food, beverages (except plain water), and calcium supplements reduce absorption. Avoid any food or drink for at least 30 minutes after dosing. Do not take with mineral water, coffee, tea, juice, or dairy products. Calcium, iron, magnesium, or aluminum-containing antacids should be taken at a different time of day.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second/third trimester: Potential for maternal hypocalcemia affecting fetal bone development. No adequate human studies. Risk cannot be excluded.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Unknown: Excretion in human milk is unknown but likely low due to high protein binding and short half-life. M/P ratio not established. Use with caution in breastfeeding due to potential for bone growth suppression in infants; alternatives preferred.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No formal dose adjustments studied. Pregnancy may increase bone turnover and renal clearance, but data insufficient to recommend dose change. Use lowest effective dose only if clearly needed. Avoid during pregnancy unless benefit outweighs risk.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
ATELVIA (risedronate) is a bisphosphonate for osteoporosis. Must be taken on an empty stomach with plain water only, at least 30 minutes before first food, drink, or other medication. Avoid in severe renal impairment (Cr Cl <30 m L/min). Monitor for hypocalcemia before initiation. Advise patients to remain upright for 30 minutes post-dose to reduce esophageal irritation.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take ATELVIA first thing in the morning, at least 30 minutes before any food, drink, or other medications.,Swallow the tablet whole with a full glass (6-8 oz) of plain water only; do not use mineral water, coffee, tea, or juice.,Do not chew, crush, or suck the tablet; remain upright (sitting or standing) for at least 30 minutes after taking.,If you miss a dose, skip it and take the next dose the following morning; do not take two doses on the same day.,Report symptoms of esophageal irritation such as difficulty or pain with swallowing, chest pain, or heartburn.,Ensure adequate intake of calcium and vitamin D as directed by your healthcare provider.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ATELVIA vs ALFENTA, answered by our medical review team.
ATELVIA is a Bisphosphonate that works by Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ATELVIA and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ATELVIA is: 35 mg orally once weekly on the same day each week, taken with at least 240 m L of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ATELVIA and ALFENTA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ATELVIA is classified as Category C. Category C: In animal studies, bisphosphonates cause fetal skeletal abnormalities at high doses. During first trimester, theoretical risk of skeletal formation interference. Second. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.